Profit Or Loss [Abstract]

OSE Immunotherapeutics - Filing #2816794

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue
26 306 EUR
10 432 EUR
Profit (loss) from operating activities
16 625 EUR
18 989 EUR
Finance income
267,000 EUR
31,000 EUR
Finance costs
856,000 EUR
288,000 EUR
Profit (loss) before tax
17 213 EUR
19 246 EUR
Tax expense (income)
364,000 EUR
2 692 EUR
Profit (loss)
16 850 EUR
16 850 EUR
16 555 EUR
16 555 EUR
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent
16 850 EUR
16 555 EUR
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share
93.00
106.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share
93.00
106.00

Talk to a Data Expert

Have a question? We'll get back to you promptly.